moderna

View online

Raising Vaccination Confidence for the 2023–2024 COVID-19 Season

Dear Provider,

Please join us for one of our upcoming events detailing the recent authorization of the updated Moderna COVID-19 Vaccine (2023–2024 Formulation).

In-depth Panel Discussion *(Webinar format, 45 minutes)*
On Tuesday, September 19 at 12 pm ET, a panel of national experts will be discussing:

- Details about the Moderna COVID-19 Vaccine (2023–2024 Formulation)
- Latest ACIP recommendations
- Strategies for building confidence in vaccination for the 2023-2024 COVID-19 season

MSL Briefings *(Q&A format, 30 minutes)*
Over the next few weeks, Moderna MSLs will host several virtual briefings to review details about the Moderna COVID-19 Vaccine (2023–2024 Formulation), including:

- ACIP recommendations
- Dosing and administration
- Storage and handling
- Safety and efficacy data

Panel Discussion

Building Vaccination Confidence for the 2023–2024 COVID-19 Season

45-minute discussion with national experts

RSVP for Webinar*

MSL Briefings

Details about the Moderna COVID-19 Vaccine (2023–2024 Formulation)

15-minute presentations followed by a live Q&A

Pick Your Date

** In order to receive a webinar replay link, you must be registered for that event. Also, you're welcome to attend multiple events but please register for each date separately.*

Boost Vaccination Confidence with Bench2Practice Resources

Access real-world data on vaccine uptake and disease burden, understand viruses impacting your community, and learn how to combat misinformation among your patients.

Start Exploring

AUTHORIZED USE

- Moderna COVID-19 Vaccine (2023-2024 Formula) has not been approved or licensed by the FDA, but has been authorized by the FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 6 months through 11 years of age.

- The EUA for this product is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner.
- For more information on the EUA authorized uses of the vaccine, refer to the Fact Sheet for Healthcare Providers Administering Vaccine.

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer the vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent.

Warnings and Precautions

- **Management of Acute Allergic Reactions:** Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the vaccine. Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).
- **Myocarditis and Pericarditis:** Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. The observed risk is highest in males 18 through 24 years of age. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).
- **Syncope (fainting):** May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
- **Altered Immunocompetence:** Immunocompromised persons, including individuals receiving immunosuppressive therapy, may

have a diminished response to Moderna COVID-19 Vaccine.
- **Limitations of Vaccine Effectiveness:** The Moderna COVID-19 Vaccine may not protect all vaccine recipients.

Adverse Reactions

Solicited adverse reactions included:

- **6 months through 36 months of age:** Injection site erythema, pain and swelling; axillary (or groin) swelling/tenderness, fever, irritability/crying, loss of appetite and sleepiness
- **37 months of age and older:** Injection site erythema, pain and swelling; arthralgia, axillary (or groin) swelling/tenderness, chills, fatigue, fever, headache, myalgia, nausea/vomiting, and rash

Reporting Adverse Events and Vaccine Administration Errors
Vaccination providers must report the listed events following administration of the Moderna COVID-19 Vaccine (2023-2024 Formula) to the Vaccine Adverse Event Reporting System (VAERS):

- vaccine administration errors whether or not associated with an adverse event
- serious adverse events (irrespective of attribution to vaccination)
- cases of myocarditis
- cases of pericarditis
- cases of Multisystem Inflammatory Syndrome (MIS)
- cases of COVID-19 that result in hospitalization or death

Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1-800-822-7967. Reports should include the words "Moderna COVID-19 Vaccine (2023-2024 Formula) EUA" in the description section of the report.

In addition, you can report side effects to ModernaTX, Inc. at 1-866-MODERNA (1-866-663-3762) or by visiting https://report.moderna.convergehealthsafety.com/.

Please see the Moderna COVID-19 Vaccine (2023-2024 Formula) Fact Sheet for Healthcare Providers Administering Vaccine and Letter of Authorization for more information.

Blog | Newsroom | Contact Us

© 2023 Moderna, Inc. All rights reserved
200 Technology Square, Cambridge, MA 02139

Please click here to manage your communication preferences.

MED-US-mRNA1273.815-2300002 09/2023